COVID-19 and Diarylamidines: The Parasitic Connection

Area of Science:

• Virology and Parasitology
• Drug Discovery and Development
• Immunology and Epigenetics

Background:

• Emerging SARS-CoV-2 variants (Omicron) challenge existing vaccines and antibody therapies targeting the spike protein's receptor-binding domain (RBD).
• Focus is shifting towards long COVID treatments, but effective therapies for post-COVID-19 syndrome are lacking due to diagnostic challenges.
• Alternative strategies are needed to reduce SARS-CoV-2 infection and prevent long COVID sequelae.

Purpose of the Study:

• To investigate diarylamidines as potential therapeutic agents against SARS-CoV-2.
• To explore the role of diarylamidines in inhibiting viral entry mechanisms.
• To examine the potential of diarylamidines in mitigating long COVID symptoms and enhancing vaccine efficacy.

Main Methods:

• Review of the parasitic-diarylamidine connection.
• Analysis of the renin-angiotensin system (RAS), ACE2, and TMPRSSR2 in SARS-CoV-2 infection.
• Discussion of diarylamidines' ability to inhibit S-protein binding and serine proteases.

Main Results:

• Diarylamidines show potential for inhibiting SARS-CoV-2 entry by targeting S-protein binding.
• These compounds may also inhibit key host proteases like TMPRSSR2 involved in viral infection.
• Preliminary evidence suggests diarylamidines could influence vaccine efficacy and epigenetic modifications.

Conclusions:

• Diarylamidines, particularly DIZE, represent a promising therapeutic avenue for combating SARS-CoV-2 and its long-term effects.
• Further research into diarylamidines is warranted for developing novel treatments for COVID-19 and post-COVID-19 syndrome.
• The multifaceted roles of diarylamidines in viral inhibition, epigenetics, and vaccine response require comprehensive investigation.